Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101
- Citation:
- Blood vol 114 (22) -210
- Meeting Instance:
- ASH 2009
- Year:
- 2009
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 228
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- T. S. Lin K. A. Donohue J. C. Byrd M. S. Lucas E. Hoke E. M. Bengtson J. N. Atkins B. K. Link K. R. Rai R. A. Larson
- Networks:
- Study
- CALGB-10101
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: